Veradermics, Incorporated
MANE
$126.89
$7.526.30%
NYSE
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -24.65% | -119.08% | |||
| Total Depreciation and Amortization | -- | -- | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 608.90% | -52.79% | |||
| Change in Net Operating Assets | 109.65% | -274.88% | |||
| Cash from Operations | 10.41% | -266.66% | |||
| Capital Expenditure | -- | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 7.72% | -- | |||
| Cash from Investing | 7.72% | -- | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -84.14% | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 79.99% | -83.26% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 810.51% | -144.23% | |||